Skip to main content
OpenTrials
Completed

NCT Number: NCT03034928

Clinical Biocompatibility Evaluation of Contact Lens Coatings

The primary objective is to evaluate corneal staining observed after 2 hours of wear with contact lenses with investigational coating against PureVision™ lenses, all pre-cycled with OPTI-FREE® RepleniSH® multi-purpose disinfection solution.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Alcon Investigative Site

Johns Creek, Georgia, 30097, United States

About this study

In this contralateral crossover study, qualifying subjects will wear a total of 2 pairs of study contact lenses. Lenses will be worn according to a randomized lens sequence assignment. Each pair will consist of a test lens (Test 1 or Test 2) and a control lens.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to understand and must sign an Informed Consent;
  • Successful wearer of spherical soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months;
  • Manifest cylinder less than or equal to 1.50 diopter (D) in each eye;
  • Best Corrected Visual Acuity (BCVA) 20/25 or better in each eye;
  • VA with habitual spectacles 20/40 in both eyes (OU) or better and willing to wear spectacles as needed during the washout period and during study lens exposure;
  • Other protocol-specified inclusion criteria may apply.

Exclusion criteria

  • Any anterior segment infection, inflammation, abnormality or disease that contraindicates contact lens wear;
  • Any use of systemic or ocular medications for which contact lens wear could be contraindicated;
  • History of refractive surgery or plan to have refractive surgery during the study or irregular cornea in either eye;
  • Ocular or intra-ocular surgery (excluding placement of punctal plugs) within the previous 12 months or planned during the study;
  • Current or history of pathologically dry eye in either eye that would preclude contact lens wear;
  • Current or history of herpetic keratitis in either eye;
  • Eye injury in either eye within 12 weeks immediately prior to enrollment;
  • History of intolerance or hypersensitivity to any component of the study lenses or solutions;
  • Habitual contact lenses worn in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment;
  • Use of topical ocular medications and artificial tear or rewetting drops that would require instillation during contact lens wear;
  • Other protocol-specified exclusion criteria may apply.

Treatment and study plan

Contact lens with investigational coating 1

Device

Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)

Other names: Test 1

Balafilcon A contact lens

Device

Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS

Other names: Bausch & Lomb PureVision™, Control 1, Control 2

OPTI-FREE® RepleniSH® MPDS

Device

Multipurpose contact lens solution

Contact lens with investigational coating 2

Device

Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS

Other names: Test 2

Primary outcomes

  1. Average Percent Area of Solution-related Corneal Staining

    Time frame: Day 1 after 2 hours of wear, each product

    Percent of solution-related corneal staining area was assessed first in each of the 5 corneal regions: central, superior, nasal, inferior, and temporal. The average of corneal staining area was then calculated as the average over all 5 regions. A higher percentage reflects more damage to the corneal surface. Both eyes contributed to the analysis. No hypotheses were formulated; no inferences were made and only descriptive statistics were used in the reporting.

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Jan 27, 2017
Registry last updated
Feb 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.